Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) (ALL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04954326
Recruitment Status : Recruiting
First Posted : July 8, 2021
Last Update Posted : July 8, 2021
Sponsor:
Collaborators:
ADIR, a Servier Group company
Les Laboratoires Servier (L.L.S), Russia
Information provided by (Responsible Party):
Servier ( Institut de Recherches Internationales Servier )

Brief Summary:
The purpose of this study is to compare the pharmacokinetics (PK) of both lyophilized and liquid S95014 formulations during the induction phase after a single IV dose in newly diagnosed paediatric patients with ALL

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Drug: Lyophilized S95014 Drug: Liquid S95014 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of the Liquid and the Lyophilized Formulations of Pegaspargase (S95014) in Treatment of Paediatric Patients With Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)
Actual Study Start Date : May 7, 2021
Estimated Primary Completion Date : April 22, 2022
Estimated Study Completion Date : April 22, 2022


Arm Intervention/treatment
Experimental: S95014 lyophilizate
Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.
Drug: Lyophilized S95014

Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.

Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.


Active Comparator: S95014 liquid
Liquid S95014 is provided as 3.750 U per 5 mL solution in a single use vial to obtain a 750 U/mL solution for single use.
Drug: Liquid S95014

Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.

Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.





Primary Outcome Measures :
  1. Pharmacokinetics measurement [ Time Frame: Day 3 pre-dose just after the infusion,4h after the end of infusion; Day 4: 24h after the end of infusion; Day 5: 48h after the end of infusion; Day 8, Day 10, Day 12, Day 17, Day 21, Day 28 ]
    Area Under the Concentration-Time Curve (AUC)

  2. Pharmacokinetics measurement [ Time Frame: Day 3 pre-dose just after the infusion,4h after the end of infusion; Day 4: 24h after the end of infusion; Day 5: 48h after the end of infusion; Day 8, Day 10, Day 12, Day 17, Day 21, Day 28 ]
    Maximum observed plasma asparaginase activity (Cmax)


Secondary Outcome Measures :
  1. Pharmacokinetics measurements [ Time Frame: 14 days post-dose ]
    Additional PK parameters from the ones defined as primary endpoint (e.g. Ctrough at 14 days post-dose) will be assessed.

  2. Activity measurement [ Time Frame: Day 10, Day 17, Day 21 and Day 28 of induction ]
    Plasma Asparaginase Activity (PAA) of ≥ 0.1 U/mL after the administration of either liquid or lyophilized S95014.

  3. Immunogenicity measurements [ Time Frame: Day 3 pre-dose, Day 17 and Day 28 ]
    Anti S95014 and anti-PEG antibodies will be assessed for both lyophilized and liquid S95014 formulations.

  4. Incidence of Treatment Emergent Adverse Events (safety and tolerability assessments) [ Time Frame: Through study completion, an average of 1 year ]
    Treatment Emergent Adverse Events (TEAEs) causality and severity based on NCI CTCAE 5.0.

  5. Incidence of Serious Adverse Event (safety assessments) [ Time Frame: Through study completion, an average of 1 year ]
    Serious Adverse Event (SAEs) causality and severity based on NCI CTCAE 5.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 1 to < 18 years
  • Patients with cytologically confirmed and documented newly diagnosed ALL according to National Comprehensive Cancer Network guidelines 2020 (see Appendix 2), excluding B-cell Burkitt ALL
  • Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2 (see Appendix 3)
  • Highly effective contraception method
  • Signed informed consent and assent, when appropriate

Non-inclusion Criteria:

  • Unlikely to cooperate in the study
  • Pregnant and lactating women
  • Participation in another interventional study at the same time; participation in non-interventional registries or epidemiological studies is allowed
  • Participant already enrolled in the study (informed consent signed)
  • Women of childbearing potential tested positive in a serum pregnancy test within 7 days prior to the treatment period
  • Inadequate hepatic function (bilirubin > 1.5 times upper limit of normal (ULN), transaminases > 5x ULN)
  • Inadequate renal function defined as serum creatinine > 1.5 x ULN
  • Prior treatment with chemotherapy or radiotherapy (except steroids and intrathecal therapy)
  • Prior surgery or bone marrow transplant related to the studied disease
  • Down Syndrome
  • Psychiatric illness/social situation that would limit compliance with study requirements
  • Known history of pancreatitis
  • Known history of significant liver disease
  • Known carriers of HIV antibodies
  • Significant laboratory abnormality likely to jeopardize the patients' safety or to interfere with the conduct of the study, in the investigator's opinion
  • Pre-existing known coagulopathy (e.g. haemophilia and known protein S deficiency)
  • History of previous or concurrent malignancy
  • History of sensitivity to polyethylene glycol (PEG) or PEG-based drugs
  • Severe or uncontrolled active acute or chronic infection
  • Uncontrolled intercurrent illness including life-threatening acute tumor lysis syndrome (e.g. with renal failure), symptomatic congestive heart failure, cardiac arrhythmia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04954326


Contacts
Layout table for location contacts
Contact: Institut de Recherches Internationales Servier Clinical Studies Department +33 1 55 72 43 66 clinical.trial.management@servier.com

Locations
Layout table for location information
Russian Federation
Regional Children Clinical Hospital Recruiting
Chelyabinsk, Russian Federation, 454087
Regional Children Clinical Hospital Not yet recruiting
Ekaterinburg, Russian Federation, 620149
Children Regional Clinical Hospital Not yet recruiting
Krasnodar, Russian Federation, 350007
Russian Children Clinical Hospital Not yet recruiting
Moscow, Russian Federation, 119571
Regional Children Hospital Recruiting
Nizhny Novgorod, Russian Federation, 603136
Children City Hospital #1 Not yet recruiting
Saint Petersburg, Russian Federation, 198205
Sponsors and Collaborators
Institut de Recherches Internationales Servier
ADIR, a Servier Group company
Les Laboratoires Servier (L.L.S), Russia
Investigators
Layout table for investigator information
Principal Investigator: Alexander Isaakovich Karachunskiy, PhD Director of Institute of Oncology, Radiology and Nuclear Medicine. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.
Additional Information:
Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Institut de Recherches Internationales Servier
ClinicalTrials.gov Identifier: NCT04954326    
Other Study ID Numbers: CL2-95014-002
2020-004894-29 ( EudraCT Number )
First Posted: July 8, 2021    Key Record Dates
Last Update Posted: July 8, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards
  • for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: After Marketing Authorisation in EEA or US if the study is used for the approval.
Access Criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
URL: https://clinicaltrials.servier.com/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Servier ( Institut de Recherches Internationales Servier ):
Oncology / Haematology
Phase II
Acute Lymphoblastic Leukemia
Parallel group
Pegaspargase
Pharmacokinetics comparability
Lyophilized pegaspargase
Liquid pegaspargase
Pegaspargase formulation
Randomized, open-label
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases